Overview

Quark Biotech Inc. is a genomics-based drug discovery and pharmaceutical company with research programs in the areas of cancer fibrosis, ischemic/vascular diseases and bone and cartilage diseases. The company is based in Cleveland, with additional research facilities located in Chicago and at the Weizmann Science Park in Ness-Ziona, Israel.

The company’s Biological Integrated Functional Array (BiFAR) high-throughput platform is designed to focus on and identify small numbers of critical genes that are targets for the specific areas being researched. The platform includes differential expression profiling that uses DNA chips and RNA probes, and functional profiling, as well as bioinformatic algorithms and statistical correlation analysis.

Quark has product candidates in the areas of oncology and cardiovascular and bone diseases.

Partners

Partners in research, gene discovery and/or target development include AstraZeneca plc, Fujisawa Pharmaceutical Co. Ltd., Mitsubishi-Tokyo Pharmaceuticals Inc., Sankyo Co. Ltd., Shionogi & Co. Ltd. and Taisho Pharmaceutical Co. Ltd. Partners for diagnostics development and/or expression systems commercialization include Perkin-Elmer Corp. and Invitrogen Corp.

In addition to corporate collaborations, Quark works with a number of academic and non-profit institutions, including the Cleveland Clinic Foundation; the University of Illinois at Chicago; the New York Blood Cancer Center; Mount Sinai Hospital, New York; Memorial Sloan Kettering Cancer Center, New York; Children’s Hospital, Boston; University of Minnesota; Washington University in St. Louis; University of Edinburgh; INSERM (U488), Paris; the Karolinska Institute; Institute of Pharmacology, Polish Academy of Sciences, Krakow; Hebrew University in Israel; Tel Aviv University; the Weizmann Institute of Science; the Institute of Molecular Biology in Moscow; Moscow State University, Gene Bee Group, in Moscow; and ES Cell International Pte. Ltd.